Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.

Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC.

Br J Haematol. 2020 Feb 4. doi: 10.1111/bjh.16425. [Epub ahead of print]

PMID:
32017050
2.

Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials.

Atkinson TM, Dueck AC, Satele DV, Thanarajasingam G, Lafky JM, Sloan JA, Basch E.

JAMA Oncol. 2019 Dec 26. doi: 10.1001/jamaoncol.2019.5566. [Epub ahead of print] No abstract available.

PMID:
31876902
3.

Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia.

Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, Lin Y, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P.

Am J Hematol. 2020 Mar;95(3):274-281. doi: 10.1002/ajh.25697. Epub 2019 Dec 31.

PMID:
31814157
4.

Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.

Dueck AC, Scher HI, Bennett AV, Mazza GL, Thanarajasingam G, Schwab G, Weitzman AL, Rogak LJ, Basch E.

JAMA Oncol. 2019 Sep 26. doi: 10.1001/jamaoncol.2019.3332. [Epub ahead of print]

PMID:
31556911
5.

Impact of lymphoma survivorship clinic visit on patient-centered outcomes.

Viscuse P, Yost KJ, Jenkins S, Lackore K, Habermann T, Thanarajasingam G, Thompson C.

J Cancer Surviv. 2019 Jun;13(3):344-352. doi: 10.1007/s11764-019-00756-y. Epub 2019 Apr 26.

PMID:
31028525
6.

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.

Goyal G, Ravindran A, Young JR, Shah MV, Bennani NN, Patnaik MM, Nowakowski GS, Thanarajasingam G, Habermann TM, Vassallo R, Sher T, Parikh SA, Rech KL, Go RS; Mayo Clinic Histiocytosis Working Group.

Haematologica. 2020 Jan 31;105(2):348-357. doi: 10.3324/haematol.2019.219626. Print 2020.

7.

Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?

Thanarajasingam G, Maurer MJ, Habermann TM, Nowakowski GS, Bennani NN, Thompson CA, Cerhan JR, Witzig TE.

Nutr Cancer. 2018 Oct;70(7):1088-1090. doi: 10.1080/01635581.2018.1502328. Epub 2018 Sep 20.

PMID:
30235018
8.

Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop.

Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger CS, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O'Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ.

Value Health. 2018 Jun;21(6):742-747. doi: 10.1016/j.jval.2017.09.009. Epub 2017 Nov 7.

9.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM.

Lancet Haematol. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18. Review. Erratum in: Lancet Haematol. 2019 Mar;6(3):e121.

10.

Primary Skull Base Lymphoma: Manifestations and Clinical Outcomes of a Great Imitator.

Marinelli JP, Modzeski MC, Lane JI, Van Gompel JJ, Stokken JK, Thanarajasingam G, Carlson ML.

Otolaryngol Head Neck Surg. 2018 Oct;159(4):643-649. doi: 10.1177/0194599818773994. Epub 2018 May 8.

PMID:
29734937
11.

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D.

Eur J Cancer. 2018 Apr;93:57-68. doi: 10.1016/j.ejca.2018.01.073. Epub 2018 Feb 21.

12.

Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.

Thanarajasingam G, Maurer MJ, Farooq U, Johnston PB, Thompson CA, Bennani NN, Ansell SM, Porrata LF, Macon WR, Syrbu SI, Cerhan JR, Habermann TM, Link BK, Witzig TE, Nowakowski GS.

Br J Haematol. 2018 Oct;183(1):149-152. doi: 10.1111/bjh.14922. Epub 2017 Sep 29. No abstract available.

13.

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.

Farooq U, Maurer MJ, Thompson CA, Thanarajasingam G, Inwards DJ, Micallef I, Macon W, Syrbu S, Lin T, Lin Y, Ansell SM, Nowakowski GS, Habermann TM, Cerhan JR, Link BK.

Br J Haematol. 2017 Oct;179(1):50-60. doi: 10.1111/bjh.14813. Epub 2017 Jun 27.

14.

Complete Response of Anaplastic Lymphoma Kinase-Mutated Refractory Extranodal Natural Killer/T-Cell Lymphoma to Crizotinib.

Thanarajasingam G, Edell ES, Markovic SM.

Mayo Clin Proc. 2016 Sep;91(9):1319-20. doi: 10.1016/j.mayocp.2016.06.014. No abstract available.

PMID:
27594191
15.

Capturing and Incorporating Patient-Reported Outcomes into Clinical Trials: Practical Considerations for Clinicians.

Botero JP, Thanarajasingam G, Warsame R.

Curr Oncol Rep. 2016 Oct;18(10):61. doi: 10.1007/s11912-016-0549-2. Review.

PMID:
27525737
16.

Adverse event development in clinical oncology trials - Authors' reply.

Thanarajasingam G, Sloan JA, Grothey A.

Lancet Oncol. 2016 Jul;17(7):e264-e265. doi: 10.1016/S1470-2045(16)30245-5. No abstract available.

PMID:
27396640
17.

Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis.

Hamadah AM, Thanarajasingam G, Gharaibeh KA, Finnes HD, Thompson CA, Leung N.

Leuk Lymphoma. 2017 Feb;58(2):457-460. Epub 2016 Jun 7. No abstract available.

PMID:
27268591
18.

Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.

Thanarajasingam G, Atherton PJ, Novotny PJ, Loprinzi CL, Sloan JA, Grothey A.

Lancet Oncol. 2016 May;17(5):663-70. doi: 10.1016/S1470-2045(16)00038-3. Epub 2016 Apr 12.

19.

PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma.

Thanarajasingam G, Bennani-Baiti N, Thompson CA.

Curr Treat Options Oncol. 2016 May;17(5):24. doi: 10.1007/s11864-016-0399-z. Review.

PMID:
27032646
20.

Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma.

Bennani-Baiti N, Thanarajasingam G, Ansell S.

Expert Rev Clin Immunol. 2016 Jun;12(6):673-9. doi: 10.1586/1744666X.2016.1147350. Epub 2016 Feb 17. Review.

PMID:
26818843
21.

Immune checkpoint blockade in lymphoid malignancies.

Thanarajasingam G, Thanarajasingam U, Ansell SM.

FEBS J. 2016 Jun;283(12):2233-44. doi: 10.1111/febs.13668. Epub 2016 Feb 22. Review.

22.

The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials.

Thanarajasingam G, Hubbard JM, Sloan JA, Grothey A.

J Natl Cancer Inst. 2015 Aug 1;107(10). pii: djv216. doi: 10.1093/jnci/djv216. Print 2015 Oct.

PMID:
26232762
23.

Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer.

Kasi PM, Thanarajasingam G, Finnes HD, Villasboas Bisneto JC, Hubbard JM, Grothey A.

Case Rep Oncol Med. 2015;2015:420159. doi: 10.1155/2015/420159. Epub 2015 May 21.

24.

Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation.

Kekre N, Kim HT, Thanarajasingam G, Armand P, Antin JH, Cutler C, Nikiforow S, Ho VT, Koreth J, Alyea EP, Soiffer RJ.

Haematologica. 2015 Sep;100(9):1222-7. doi: 10.3324/haematol.2015.129650. Epub 2015 Jun 18.

25.

Paraneoplastic encephalopathy: an unusual presenting feature of bladder cancer metastasis.

Thanarajasingam G, Milone M, Kohli M.

BMJ Case Rep. 2015 May 4;2015. pii: bcr2014208913. doi: 10.1136/bcr-2014-208913.

26.

Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance).

Barton DL, Thanarajasingam G, Sloan JA, Diekmann B, Fuloria J, Kottschade LA, Lyss AP, Jaslowski AJ, Mazurczak MA, Blair SC, Terstriep S, Loprinzi CL.

Cancer. 2014 Nov 15;120(22):3575-83. doi: 10.1002/cncr.28892. Epub 2014 Jul 9.

27.

Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.

Thanarajasingam G, Kim HT, Cutler C, Ho VT, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Armand P.

Biol Blood Marrow Transplant. 2013 Dec;19(12):1713-8. doi: 10.1016/j.bbmt.2013.09.011. Epub 2013 Sep 27.

28.

Accessory splenectomy for refractory immune thrombocytopenic purpura.

Thanarajasingam G, Vaidya R, Erie A, Wolanskyj AP.

Am J Hematol. 2011 Jun;86(6):520-3. doi: 10.1002/ajh.22011. Epub 2011 Apr 25. No abstract available.

29.

39-year-old woman with an obscure case of anemia.

Palmer SR, Thanarajasingam G, Wolanskyj AP.

Mayo Clin Proc. 2010 Jan;85(1):e1-4. doi: 10.4065/mcp.2008.0721. No abstract available.

30.

Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.

Gangat N, Tefferi A, Thanarajasingam G, Patnaik M, Schwager S, Ketterling R, Wolanskyj AP.

Eur J Haematol. 2009 Jul;83(1):17-21. doi: 10.1111/j.1600-0609.2009.01246.x. Epub 2009 Feb 19.

PMID:
19236446
31.

Intentional ingestion of ethanol-based hand sanitizer by a hospitalized patient with alcoholism.

Thanarajasingam G, Diedrich DA, Mueller PS.

Mayo Clin Proc. 2007 Oct;82(10):1288-9. No abstract available.

PMID:
17908534
32.

Estrogen enhances light-induced activation of dorsal raphe serotonergic neurons.

Abizaid A, Mezei G, Thanarajasingam G, Horvath TL.

Eur J Neurosci. 2005 Mar;21(6):1536-46.

PMID:
15845081

Supplemental Content

Loading ...
Support Center